Table 5. Frequency of genotypes at SNPs rs11615 and rs3212986 in the ERCC1 gene in malignant patients based on sensitivity to cisplatin and carboplatin .
| Total Frequency | Responders | Non-responders | OR (95% CI) | P value | |
| PR+CR | SD+PD | ||||
| Genotype (rs11615) | |||||
| Cisplatin | |||||
| TT | 2 | 1 | 1 | 1.001 (0.041, 24.547) | 0.999 |
| TC | 19 | 6 | 13 | 2.166 (0.334, 14.057) | 0.418 |
| CC | 6 | 3 | 3 | Ref. | |
| Carboplatin | |||||
| TT | 3 | 2 | 1 | 0.375 (0.022, 6.348) | 0.497 |
| TC | 3 | 1 | 2 | 1.500 (0.089, 25.392) | 0.779 |
| CC | 7 | 3 | 4 | Ref. | |
| Genotype (rs3212986) | |||||
| Cisplatin | |||||
| AA | 5 | 3 | 2 | 0.667 (0.069, 6.409) | 0.725 |
| AC | 14 | 3 | 11 | 3.667 (0.5557, 24.132) | 0.177 |
| CC | 8 | 4 | 4 | Ref. | |
| Carboplatin | |||||
| AA | 4 | 1 | 3 | 3.000 (0.188, 47.963) | 0.437 |
| AC | 3 | 2 | 1 | 0.500 (0.028, 8.952) | 0.638 |
| CC | 6 | 3 | 3 | Ref. | |
Note. SNP: single-nucleotide polymorphism; CI: Confidence interval; OR: Odds ratio. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.